LAP3 and diabetes mellitus: Peptidomimetics guarantee enhanced protection against peptidases, improved systemic delivery and cell penetration, high target specificity and poor immune response and they are already in use against different pathologies, such as cancer and diabetes (Vagner et al., 2008; Zhang et al., 2018).